• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    4/19/23 9:06:16 AM ET
    $ALLR
    $BVXV
    $CNSP
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALLR alert in real time by email

    Gainers

    • Virax Biolabs Group (NASDAQ:VRAX) shares rose 34.2% to $0.81 during Wednesday's pre-market session. The market value of their outstanding shares is at $12.5 million.
    • Genprex (NASDAQ:GNPX) stock increased by 15.78% to $1.1. The company's market cap stands at $57.1 million.
    • Matinas BioPharma Hldgs (AMEX:MTNB) shares moved upwards by 14.85% to $0.58. The market value of their outstanding shares is at $126.0 million.
    • VYNE Therapeutics (NASDAQ:VYNE) stock increased by 14.37% to $3.58. The market value of their outstanding shares is at $11.6 million.
    • BiondVax Pharmaceuticals (NASDAQ:BVXV) stock rose 14.35% to $2.23. The market value of their outstanding shares is at $4.2 million. The company's, Q4 earnings came out 2 days ago.
    • Legend Biotech (NASDAQ:LEGN) shares rose 13.89% to $59.5. The market value of their outstanding shares is at $9.8 billion.

    Losers

    • Femasys (NASDAQ:FEMY) stock declined by 26.2% to $0.93 during Wednesday's pre-market session. The company's market cap stands at $11.0 million.
    • Allarity Therapeutics (NASDAQ:ALLR) stock decreased by 23.28% to $0.89.
    • SAB Biotherapeutics (NASDAQ:SABS) stock fell 14.66% to $0.93. The company's market cap stands at $46.8 million. As per the news, the Q4 earnings report came out 3 days ago.
    • Indaptus Therapeutics (NASDAQ:INDP) shares decreased by 14.11% to $2.12. The company's market cap stands at $17.8 million.
    • CNS Pharma (NASDAQ:CNSP) shares declined by 12.23% to $1.79. The market value of their outstanding shares is at $3.9 million.
    • Dermata Therapeutics (NASDAQ:DRMA) stock fell 9.89% to $2.28. The company's market cap stands at $1.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR
    $BVXV
    $CNSP
    $DRMA

    CompanyDatePrice TargetRatingAnalyst
    Legend Biotech Corporation
    $LEGN
    2/12/2026$24.00Buy → Neutral
    Rothschild & Co Redburn
    Legend Biotech Corporation
    $LEGN
    1/22/2026$21.00Buy → Hold
    TD Cowen
    Legend Biotech Corporation
    $LEGN
    1/7/2026$75.00Outperform
    Oppenheimer
    SAB Biotherapeutics Inc.
    $SABS
    12/19/2025$15.00Buy
    Guggenheim
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    Legend Biotech Corporation
    $LEGN
    10/7/2025$40.00Overweight
    Cantor Fitzgerald
    SAB Biotherapeutics Inc.
    $SABS
    9/17/2025$7.00Outperform
    Leerink Partners
    VYNE Therapeutics Inc.
    $VYNE
    7/31/2025Buy → Neutral
    BTIG Research
    More analyst ratings

    $ALLR
    $BVXV
    $CNSP
    $DRMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lepore Patrick G bought $43,800 worth of shares (15,000 units at $2.92), increasing direct ownership by 41% to 51,472 units (SEC Form 4)

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    1/16/25 6:06:19 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gumulka Jerzy bought $10,000 worth of shares (33,333 units at $0.30), increasing direct ownership by 345% to 43,006 units (SEC Form 4)

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    2/6/24 10:28:10 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evans Carl Anthony bought $10,000 worth of shares (33,333 units at $0.30), increasing direct ownership by 26,666% to 33,458 units (SEC Form 4)

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    2/6/24 10:27:56 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BVXV
    $CNSP
    $DRMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

    -- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical data -- ATLANTA, March 10, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the initiation of patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc. This milestone follows U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to advance the study based on positive clinical data generated in its

    3/10/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

    Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced additional data from the Phase 1 HUman anti-thymocyte biologic in first-in-MAN (HUMAN) clinical trial of SAB-142. The established T1D adult patient cohort demonstrated early signals of C-peptide preservation which aligned with the anticipated mechanism of action o

    3/10/26 7:31:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genprex to Participate at BIO Europe Spring 2026

    AUSTIN, Texas, March 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating at BIO Europe Spring taking place March 23-25, 2026 in Lisbon, Portugal. In attendance will be Ryan Confer, President and Chief Executive Officer at Genprex and Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing at Genprex. Throug

    3/10/26 7:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BVXV
    $CNSP
    $DRMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Legend Biotech downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Legend Biotech from Buy to Neutral and set a new price target of $24.00

    2/12/26 7:23:25 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech downgraded by TD Cowen with a new price target

    TD Cowen downgraded Legend Biotech from Buy to Hold and set a new price target of $21.00

    1/22/26 8:26:15 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Legend Biotech with a new price target

    Oppenheimer initiated coverage of Legend Biotech with a rating of Outperform and set a new price target of $75.00

    1/7/26 8:37:12 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BVXV
    $CNSP
    $DRMA
    SEC Filings

    View All

    SEC Form 8-K filed by VYNE Therapeutics Inc.

    8-K - VYNE Therapeutics Inc. (0001566044) (Filer)

    3/11/26 4:57:52 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CNS Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

    3/11/26 8:35:29 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Legend Biotech Corporation

    20-F - Legend Biotech Corp (0001801198) (Filer)

    3/10/26 11:45:24 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BVXV
    $CNSP
    $DRMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Technology Officer Faulkner Eric

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    3/4/26 5:02:29 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Faulkner Eric

    3 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    3/4/26 5:02:02 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer O'Loughlin Steve

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    3/4/26 5:01:43 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BVXV
    $CNSP
    $DRMA
    Financials

    Live finance-specific insights

    View All

    Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

    CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectivelySurpassed milestone of more than 10,000 patients treated with CARVYKTI®CARVYKTI now available across 294 sites worldwide; continued expansion in U.S. community settingsAdvanced early-stage cell therapy portfolio, including first-patient dosing of in vivo candidates and presentation of first-in-human results for LUCAR-G39D, an allogeneic CAR-T therapy Cash and cash equivalents, and time deposits of $949 million, as of December 31, 2025 SOMERSET, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN)

    3/10/26 7:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results

    SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 10, 2026, to review fourth-quarter and full-year 2025 financial results. During the conference call and accompanying webcast, senior management will provide an overview of quarterly and full-year financial performance. Investors and other interested parties may access the live audio webcast via this weblink. A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presen

    2/24/26 8:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

    Following closing, combined company plans to progress Yarrow's lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor ("TSHR") antibody for Graves' disease ("GD") and thyroid eye disease ("TED")Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance in-licensed asset YB-101 (also known as GS-098) into a U.S.-based Phase 1b/2b trial in patients with GD in the first half of 2026; a Phase 1 trial in TED is being conducted in China by partner Changchun GeneScience Pharmaceutical Co., Ltd ("GenSci")Pre-closing private financings totaling approximately $200 million expected to fund operations into 2028Companies to

    12/17/25 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BVXV
    $CNSP
    $DRMA
    Leadership Updates

    Live Leadership Updates

    View All

    SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

    David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D. to its Board of Directors as Chair of the Board and the appointment of Rita Jain, M.D., as an independent director, both effective immediately. "We are excited to welcome Dr. David Zaccardelli and Dr. Rita Jain to our Board of Directors. I, along with the rest of our Board, am confi

    1/7/26 8:00:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios

    --Existing investors, including Femasys' largest shareholders, reaffirm confidence in Femasys' strategy for growth and impact in women's health-- ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today the closing of $8 million in financing. This funding will provide critical resources to accelerate commercialization efforts and strengthen the company's ability to address significant unmet needs in women's reproductive health. To underscore this momentum, Femasys' largest shareholder, Jorey Chernett also provided co

    9/2/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Legend Biotech Appoints Carlos Santos as Chief Financial Officer

    SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company's Chief Financial Officer, effective immediately. Mr. Santos assumes the role from Jessie Yeung, who has served as the interim CFO since January 2025. Mr. Santos is a seasoned finance executive who has led financial operations in the pharmaceutical and technology sectors across the United States, Latin America, Europe, the Middle East, and Africa. At Legend, he will oversee financial operations to work to ensure a robust balance sheet and achieve and maintain profitability. "On behalf

    8/18/25 8:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BVXV
    $CNSP
    $DRMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Indaptus Therapeutics Inc.

    SC 13D/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)

    11/26/24 4:11:08 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Virax Biolabs Group Limited

    SC 13G/A - Virax Biolabs Group Ltd (0001885827) (Subject)

    11/14/24 4:46:07 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care